THE NEW POLYPHARMACY IN PSYCHIATRY - CLINICAL-PRACTICE AND CLINICAL RESEARCH PART COMPANY

Citation
Df. Naftolowitz et al., THE NEW POLYPHARMACY IN PSYCHIATRY - CLINICAL-PRACTICE AND CLINICAL RESEARCH PART COMPANY, CNS DRUGS, 4(6), 1995, pp. 404-409
Citations number
19
Categorie Soggetti
Neurosciences,"Pharmacology & Pharmacy
Journal title
ISSN journal
11727047
Volume
4
Issue
6
Year of publication
1995
Pages
404 - 409
Database
ISI
SICI code
1172-7047(1995)4:6<404:TNPIP->2.0.ZU;2-6
Abstract
A trend towards increased utilisation of polypharmacy in clinical psyc hiatry has been observed recently. Among the factors contributing to t his are the emerging predominance of drug treatment for psychiatric di sorders, newer therapeutic agents, attempts to alleviate symptoms in p atients who only partially respond to treatment, and the over-interpre tation of research data. Problems with polypharmacy include the potent ial for drug interactions, the unknown safety of newer medicines, and the use of superfluous medication mixtures when one drug might suffice . The complexities inherent in the existing research methodology limit the study of polypharmacy. We suggest a new paradigm for researching multidrug regimens, modelled on that of health services research.